<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170283</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-LTE1</org_study_id>
    <nct_id>NCT04170283</nct_id>
  </id_info>
  <brief_title>Long-term Extension Study of Zanubrutinib (BGB-3111) in Participants With B-cell Malignancies</brief_title>
  <official_title>An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients With B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and efficacy of zanubrutinib in
      participants with B-cell malignancies who were previously enrolled in an eligible BeiGene
      study.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Safety as assessed by incidence of treatment-emergent adverse events (AEs) according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, and serious AEs (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Safety as assessed by incidence of treatment-emergent adverse events (AEs) according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, and serious AEs (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) per investigator assessment</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time from the starting date of zanubrutinib in the eligible BeiGene study to the date of first documentation of disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per investigator assessment</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time from the date that response criteria are first met after the start of zanubrutinib in the eligible BeiGene study to the date that progressive disease (PD) is objectively documented or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time from the starting date of zanubrutinib in the eligible BeiGene study to the date of death due to any reason</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>B-cell Malignancies</condition>
  <arm_group>
    <arm_group_label>Zanubrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants to receive open-label zanubrutinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>Participants will receive zanubrutinib at a dose of 160 mg twice daily, or the last dosing regimen in a previous, eligible BeiGene study</description>
    <arm_group_label>Zanubrutinib</arm_group_label>
    <other_name>BGB-3111</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Currently enrolled in an eligible BeiGene study or recently treated with zanubrutinib
             in an eligible BeiGene study

          2. Must meet the following criteria within 15 days before first dose of zanubrutinib:

               1. Platelets ≥ 50,000/mm3

               2. Absolute neutrophil count ≥ 750/mm3

               3. Aspartate aminotransferase and alanine aminotransferase ≤ 2 x upper limit of
                  normal

               4. Serum total bilirubin &lt; 2.5 x upper limit of normal

               5. QTcF ≤ 480 msec,

               6. No known New York Heart Association Class III or IV congestive heart failure

               7. Creatinine clearance ≥ 30 mL/min Written informed consent

        Key Exclusion Criteria:

          1. Permanently discontinued from zanubrutinib treatment in the eligible BeiGene study due
             to unacceptable toxicity, non-compliance with study procedures, or withdrawal of
             consent

          2. Uncontrolled active systemic infection or recent infection requiring parenteral
             anti-microbial therapy

          3. Life-threatening illness, medical condition or organ system dysfunction which, in the
             investigator's opinion, could compromise the participant's safety, interfere with the
             absorption or metabolism of zanubrutinib, or put the study outcomes at undue risk

          4. Concomitant chemotherapy, targeted therapy, radiation therapy, antibody-based
             therapies, or any prohibited concomitant therapy

          5. Pregnant or lactating women

          6. Inability to comply with study procedures

          7. Concurrent participation in another therapeutic clinical study

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer K. Brachmann, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Cancer Specialists and Research Institute - South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists and Research Institute - North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brisbane Clinic for Lymphoma, Myeloma and Leukaemia</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geelong University Hospital</name>
      <address>
        <city>Geelong</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research</name>
      <address>
        <city>Kurralta Park</city>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital</name>
      <address>
        <city>Malvern</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Wodonga</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zanubrutinib</keyword>
  <keyword>Bruton's tyrosine kinase (BTK) inhibitor</keyword>
  <keyword>long-term extension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

